 BASEL, Switzerland and NEW YORK, March 24, 2021 GLOBE NEWSWIRE -- Myovant Sciences NYSE: MYOV and Pfizer Inc. NYSE: PFE today announced positive data from the Phase 3 LIBERTY randomized withdrawal study of relugolix combination therapy relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg in women with uterine fibroids. This study was designed to assess the safety and efficacy of continued treatment with relugolix combination therapy for up to two years. 